Journal of Clinical Oncology, Vol 7, 108-114, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin

MG Kris, RJ Gralla, LB Tyson, RA Clark, C Cirrincione and S Groshen
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

The majority of patients receiving cisplatin at a dose of 120 mg/m2 experience delayed nausea and vomiting occurring between 24 and 120 hours after chemotherapy administration. Ninety-one patients who were receiving cisplatin (120 mg/m2) as initial chemotherapy were entered into this double-blind trial. All patients received intravenous (IV) metoclopramide, dexamethasone, and lorazepam for the control of acute emesis during the period from 0 to 24 hours after cisplatin. Patients were then randomized to one of three treatment regimens: placebo; oral dexamethasone, 8 mg twice daily for two days, then 4 mg twice daily for two days; or the combination of oral metoclopramide, 0.5 mg/kg four times daily for four days, plus oral dexamethasone administered as above. Forty-eight percent of individuals who received the two-drug combination of metoclopramide plus dexamethasone experienced delayed vomiting as opposed to 65% who were administered dexamethasone alone and 89% who received placebo (P = .006). Scores assessing the severity of delayed nausea and vomiting were consistently worse in individuals receiving placebo. The incidences of sleepiness, restlessness, heartburn, hiccoughs, loose bowel movements, insomnia, and acute dystonic reactions did not differ significantly among the three regimens and were mild and self-limited. The two-drug combination of oral metoclopramide plus dexamethasone is well tolerated, safe, and more effective than dexamethasone alone or placebo in controlling delayed vomiting following cisplatin.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. D. Kloth New pharmacologic findings for the treatment of PONV and PDNV Am. J. Health Syst. Pharm., January 1, 2009; 66(1_Supplement_1): S11 - S18. [Abstract] [Full Text] [PDF]

				K. Jordan, C. Sippel, and H.-J. Schmoll Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations Oncologist, September 1, 2007; 12(9): 1143 - 1150. [Abstract] [Full Text] [PDF]

				M. G. Kris, P. J. Hesketh, M. R. Somerfield, P. Feyer, R. Clark-Snow, J. M. Koeller, G. R. Morrow, L. W. Chinnery, M. J. Chesney, R. J. Gralla, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006 J. Clin. Oncol., June 20, 2006; 24(18): 2932 - 2947. [Abstract] [Full Text] [PDF]

				5HT3-receptor antagonists as antiemetics in cancer DTB, August 1, 2005; 43(8): 57 - 62. [Abstract] [Full Text] [PDF]

				O. Geling and H.-G. Eichler Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications J. Clin. Oncol., February 20, 2005; 23(6): 1289 - 1294. [Abstract] [Full Text] [PDF]

				M. S. Aapro, B. Thuerlimann, C. Sessa, C. de Pree, J. Bernhard, and R. Maibach A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis Ann. Onc., February 1, 2003; 14(2): 291 - 297. [Abstract] [Full Text] [PDF]

				Y. Takiguchi, R. Watanabe, K. Nagao, and T. Kuriyama Hiccups as an Adverse Reaction to Cancer Chemotherapy J Natl Cancer Inst, May 15, 2002; 94(10): 772 - 772. [Full Text] [PDF]

				R. H. Rosen Management of Chemotherapy-Induced Nausea and Vomiting Journal of Pharmacy Practice, February 1, 2002; 15(1): 32 - 41. [Abstract] [PDF]

				D. Campos, J. R. Pereira, R. R. Reinhardt, C. Carracedo, S. Poli, C. Vogel, J. Martinez-Cedillo, A. Erazo, J. Wittreich, L.-O. Eriksson, et al. Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone J. Clin. Oncol., March 15, 2001; 19(6): 1759 - 1767. [Abstract] [Full Text] [PDF]

				J. Savard and C. M. Morin Insomnia in the Context of Cancer: A Review of a Neglected Problem J. Clin. Oncol., February 1, 2001; 19(3): 895 - 908. [Abstract] [Full Text] [PDF]

				J. P. A. Ioannidis, P. J. Hesketh, and J. Lau Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence J. Clin. Oncol., October 19, 2000; 18(19): 3409 - 3422. [Abstract] [Full Text] [PDF]

				I. Henzi, B. Walder, and M. R. Tramer Dexamethasone for the Prevention of Postoperative Nausea and Vomiting: A Quantitative Systematic Review Anesth. Analg., January 1, 2000; 90(1): 186 - 186. [Abstract] [Full Text] [PDF]

				R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]

				F. Roila, E. Ballatori, A. Del Favero, R. M. Navari, A. D. Carides, and B. J. Gertz Prevention of Cisplatin-Induced Emesis by a Neurokinin-1-Receptor Antagonist N. Engl. J. Med., June 17, 1999; 340(24): 1926 - 1928. [Full Text]

				R. M. Navari and P. J. Hesketh Use of Placebos in Delayed-Emesis Studies J. Clin. Oncol., May 1, 1999; 17(5): 1644 - 1644. [Full Text] [PDF]

				R. M. Navari, R. R. Reinhardt, R. J. Gralla, M. G. Kris, P. J. Hesketh, A. Khojasteh, H. Kindler, T. H. Grote, K. Pendergrass, S. M. Grunberg, et al. Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1-Receptor Antagonist N. Engl. J. Med., January 21, 1999; 340(3): 190 - 195. [Abstract] [Full Text] [PDF]

				S. M. Grunberg and P. J. Hesketh Control of Chemotherapy-Induced Emesis N. Engl. J. Med., December 9, 1993; 329(24): 1790 - 1796. [Full Text]

				J. Herrstedt, T. Sigsgaard, M. Boesgaard, T. P. Jensen, and P. Dombernowsky Ondansetron plus Metopimazine Compared with Ondansetron Alone in Patients Receiving Moderately Emetogenic Chemotherapy N. Engl. J. Med., April 15, 1993; 328(15): 1076 - 1080. [Abstract] [Full Text]

				H. J. Durivage and N. L. Burnham Prevention and Management of Toxicities Associated With Antineoplastic Drugs Journal of Pharmacy Practice, January 1, 1991; 4(1): 27 - 48. [PDF]

				P. H. M. De Mulder, C. Seynaeve, J. B. Vermorken, P. A. van Liessum, S. Mols-Jevdevic, E. L. Allman, P. Beranek, and J. Verweij Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting: A Multicenter, Randomized, Double-Blind, Crossover Study Ann Intern Med, December 1, 1990; 113(11): 834 - 840. [Abstract] [PDF]